FDA cites litany of errors at Lonza Houston plant at the center of Bristol Myers CVR debacle
Investors’ somewhat longshot bet on a $9 CVR tied to Bristol Myers Squibb’s acquisition of Celgene came to a screeching halt last month after the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
